Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Current Leases (2021 - 2025)

Krystal Biotech (KRYS) has disclosed Current Leases for 5 consecutive years, with $1.8 million as the latest value for Q4 2025.

  • Quarterly Current Leases rose 45.52% to $1.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.8 million through Dec 2025, up 45.52% year-over-year, with the annual reading at $1.8 million for FY2025, 45.52% up from the prior year.
  • Current Leases hit $1.8 million in Q4 2025 for Krystal Biotech, up from $1.7 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $1.8 million in Q4 2025 to a low of $648000.0 in Q1 2021.
  • Historically, Current Leases has averaged $1.4 million across 5 years, with a median of $1.4 million in 2022.
  • Biggest five-year swings in Current Leases: surged 117.75% in 2022 and later fell 17.44% in 2024.
  • Year by year, Current Leases stood at $1.0 million in 2021, then surged by 49.95% to $1.6 million in 2022, then dropped by 5.57% to $1.5 million in 2023, then dropped by 17.44% to $1.2 million in 2024, then surged by 45.52% to $1.8 million in 2025.
  • Business Quant data shows Current Leases for KRYS at $1.8 million in Q4 2025, $1.7 million in Q3 2025, and $1.6 million in Q2 2025.